Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease-a dose-response relationship study

American Journal of Therapeutics

Volumn 17, Issue 6, 2010, Pages 553-558

  Saha, Sandeep A ^a,b   Lasalle, Brian K ^a   Clifton, G Dennis ^c   Short, Robert A ^a,c   Tuttle, Katherine R ^a,b  

^a SACRED HEART MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

angiotensin receptor blockers; carboxymethyl lysine; hypertension

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADRENERGIC RECEPTOR BLOCKING AGENT; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CREATININE; DIURETIC AGENT; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR BLOCKING; TREATMENT DURATION; URINALYSIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 78649659445     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181b96c27     Document Type: Article

References (31)

1. United States Renal Data System\the concise 2008 annual data report. Available online at http://www. usrds.org/2008/usrds-booklet-08.pdf. Accessed December 14,2008.
2. USRDS Annual Data Report Four: transition to end-stage renal disease. Available online at http://www.usrds. org/2008/pdf/V1-04-2008.pdf. Accessed December 14, 2008.
3. Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597-605.
4. Soulis-Liparota T, Cooper M, Papazoglou D, et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluores-cence in streptozocin-induced diabetic rat. Diabetes. 1991; 40:1328-1334.
5. Strippoli GFM, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006; Issue 4. Art. No.: CD006257. DOI: 10.1002/14651858.CD006257. (Pubitemid 46841144)
6. Miyata T, van Ypersele de Strihou C, Ueda Y, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mech-anisms. J Am Soc Nephrol. 2002;13:2478-2487.
7. Huang JS, Guh JY, Chen HC, et al. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen pro-duction in NRK-49F cells. J Cell Biochem. 2001;81:102-113.
8. Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy Diabetes. 2002;51:3274-3282.
9. Fan Q, Liao J, Kobayashi M, et al. Candesartan reduced advanced glycation end-products accumulation and di-minished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant. 2004;19:3012-3020.
10. Sebeková K, Gazd́iková K, Syrová D, et al. Effects of ramipril in nondiabetic nephropathy: improved param-eters of oxidatives stress and potential modulation of advanced glycation end products.JHum Hypertens. 2003; 17:265-270.
11. Busch M, Franke S, Wolf G, et al. Serum levels of the advanced glycation end products Nepsilon-carboxyme-thyllysine and pentosidine are not influenced by treat-ment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract. 2008;108:c291-c297.
12. Persson F, Rossing P, Hovind P, et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy Diabetes. 2006;55:3550-3555.
13. Levey AS, Bosch JP, Lewis JB, et al; for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-470.
14. Tuttle KR, Anderberg RJ, Cooney SK, et al. Oxidative stress mediates protein kinase C activation and advanced glycation end product formation in a mesangial cell model of diabetes and high protein diet. Am J Nephrol. 2008;29:171-180.
15. Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy Am J Ther. 2005; 12:562-572.
16. Bohlender JM, Franke S, Stein G, et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol. 2005;289:F645-F659.
17. Thomas MC, Tikellis C, Burns WM, et al. Interactions between renin angiotensin system and advanced glyca-tion in the kidney. J Am Soc Nephrol. 2005;16:2976-2984.
18. Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol. 2003; 14:1212-1222.
19. Matsui T, Yamagishi S, Ueda S, et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemo-attractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res. 2007;35:482-489.
20. Rossing K, Christensen PK, Hansen BV, et al. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diab Care. 2003;26:150-155.
21. Tamura Y, Kosuga M, Yamashita M, et al. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease. Clin Exp Nephrol. 2008;12:256-263.
22. Monacelli F, Poggi A, Storace D, et al. Effects of valsartan therapy on protein glycoxidation. Metabolism. 2006;55(12): 1619-1624.
23. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy Proc Natl Acad Sci USA. 2000;97:7667-7669.
24. Sharma K, Ziyadeh FN, Alzhabi B, et al. Increased renal production of transforming growth factor beta 1 in patients with type II diabetes. Diabetes. 1997;46:854-859.
25. Schmieder RE, Klingbiel AU, Fleischmann EH, et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005;16:3038-3045.
26. Fukami K, Ueda S, Yamagishi S, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 2004;66:2137-2147.
27. Tuttle KR, Johnson EC, Cooney SK, et al. Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney Int. 2005;67:953-968.
28. Coughlan MT, Mibus AL, Forbes JM. Oxidative stress and advanced glycation in diabetic nephropathy Ann N Y Acad Sci. 2008;1126:190-193.
29. Uribarri J, Cai W, Sandu O, et al. Diet-derived glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci. 2005;1043:461-466.
30. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003; 14:728-731. (Pubitemid 36246017)
31. Cai W, He JC, Zhu L, et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-acti-vated protein kinase stimulant in diabetic patients. Circulation. 2004;110:285-291.